Journal
BRAIN SCIENCES
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/brainsci11121654
Keywords
Parkinson's disease; COVID-19; SARS-CoV-2; neurodegeneration; Alzheimer's disease; viral infection
Categories
Funding
- PRACTIS-Clinician Scientist Program of Hannover Medical School - German Research Foundation (DFG) [ME 3696/3-1]
Ask authors/readers for more resources
Research on the connection between COVID-19 and Parkinson's disease is ongoing, with some evidence suggesting a potential increase in neurodegenerative diseases following the SARS-CoV-2 pandemic. However, current data are not sufficient to confirm whether COVID-19 can directly trigger or accelerate neurodegenerative diseases.
The SARS-CoV-2 pandemic has affected the daily life of the worldwide population since 2020. Links between the newly discovered viral infection and the pathogenesis of neurodegenerative diseases have been investigated in different studies. This review aims to summarize the literature concerning COVID-19 and Parkinson's disease (PD) to give an overview on the interface between viral infection and neurodegeneration with regard to this current topic. We will highlight SARS-CoV-2 neurotropism, neuropathology and the suspected pathophysiological links between the infection and neurodegeneration as well as the psychosocial impact of the pandemic on patients with PD. Some evidence discussed in this review suggests that the SARS-CoV-2 pandemic might be followed by a higher incidence of neurodegenerative diseases in the future. However, the data generated so far are not sufficient to confirm that COVID-19 can trigger or accelerate neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available